Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 85

1.

Bilateral Internal Thoracic Artery Configuration for Coronary Artery Bypass Surgery: A Prospective Randomized Trial.

Glineur D, Boodhwani M, Hanet C, de Kerchove L, Navarra E, Astarci P, Noirhomme P, El Khoury G.

Circ Cardiovasc Interv. 2016 Jul;9(7). pii: e003518. doi: 10.1161/CIRCINTERVENTIONS.115.003518.

2.

Impact of gender difference in hospital outcomes following percutaneous coronary intervention. Results of the Belgian Working Group on Interventional Cardiology (BWGIC) registry.

Lempereur M, Magne J, Cornelis K, Hanet C, Taeymans Y, Vrolix M, Legrand V.

EuroIntervention. 2016 Jun 12;12(2):e216-23. doi: 10.4244/EIJY14M12_11.

3.

Elevation of biomarkers and long-term outcome after percutaneous coronary intervention.

Slimani A, Hanet C, Jamart J, Gabriel L, Guedes A, Dangoisse V, Galanti LM, Schroeder E.

Eur J Clin Invest. 2014 Nov;44(11):1116-20. doi: 10.1111/eci.12347.

PMID:
25284363
4.

Cobalt-chromium KAname™ coRonary stEnt system in the treatment of patients with coronary artery disease (KARE study).

Carrie D, Schächinger V, Danzi GB, Macaya C, Zeymer U, Putnikovic B, Iniguez A, Moreno R, Mehmedbegovic Z, Beleslin B; KARE INVESTIGATORS..

J Interv Cardiol. 2014 Oct;27(5):491-9. doi: 10.1111/joic.12144.

PMID:
25175153
5.

Rationale and design of the Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug-Resistant Hypertension (INSPiRED) trial.

Jin Y, Jacobs L, Baelen M, Thijs L, Renkin J, Hammer F, Kefer J, Petit T, Verhamme P, Janssens S, Sinnaeve P, Lengelé JP, Persu A, Staessen JA; investigator-steered project on intravascular renal denervation for management of drug-resistant hypertension (INSPiRED) investigators..

Blood Press. 2014 Jun;23(3):138-46. doi: 10.3109/08037051.2014.899297.

6.

Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.

Camenzind E, Boersma E, Wijns W, Mauri L, Rademaker-Havinga T, Ordoubadi FF, Suttorp MJ, Al Kurdi M, Steg PG; PROTECT Steering Committee and Investigators..

Eur Heart J. 2014 Aug 1;35(29):1932-48. doi: 10.1093/eurheartj/ehu084.

PMID:
24627416
8.

Five-year follow-up of drug-eluting stents implantation vs minimally invasive direct coronary artery bypass for left anterior descending artery disease: a propensity score analysis.

Etienne PY, D'hoore W, Papadatos S, Mairy Y, El Khoury G, Noirhomme P, Hanet C, Glineur D.

Eur J Cardiothorac Surg. 2013 Nov;44(5):884-90. doi: 10.1093/ejcts/ezt137.

PMID:
23492989
9.

Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial.

Onuma Y, Miquel-Hebert K, Serruys PW; SPIRIT II Investigators..

EuroIntervention. 2013 Jan 22;8(9):1047-51. doi: 10.4244/EIJV8I9A161.

10.

Competitive flow in coronary bypass surgery: is it a problem?

Glineur D, Hanet C.

Curr Opin Cardiol. 2012 Nov;27(6):620-8. doi: 10.1097/HCO.0b013e3283583000. Review.

PMID:
23075821
11.

Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial.

Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K, Gao R, Bode C, Greenwood JP, Boersma E, Vranckx P, McFadden E, Serruys PW, O'Neil WW, Jorissen B, Van Leeuwen F, Steg PG; PROTECT Steering Committee and Investigators..

Lancet. 2012 Oct 20;380(9851):1396-405. doi: 10.1016/S0140-6736(12)61336-1.

PMID:
22951082
12.

Competitive flow and arterial graft a word of caution.

Glineur D, Hanet C.

Eur J Cardiothorac Surg. 2012 Apr;41(4):768-9. doi: 10.1093/ejcts/ezr064. No abstract available.

PMID:
22423057
13.

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators..

N Engl J Med. 2012 Jan 5;366(1):20-33. doi: 10.1056/NEJMoa1109719.

14.

Angiographic predictors of 3-year patency of bypass grafts implanted on the right coronary artery system: a prospective randomized comparison of gastroepiploic artery, saphenous vein, and right internal thoracic artery grafts.

Glineur D, D'hoore W, de Kerchove L, Noirhomme P, Price J, Hanet C, El Khoury G.

J Thorac Cardiovasc Surg. 2011 Nov;142(5):980-8. doi: 10.1016/j.jtcvs.2011.07.017.

15.

The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions.

Grube E, Chevalier B, Smits P, Džavík V, Patel TM, Mullasari AS, Wöhrle J, Stuteville M, Dorange C, Kaul U; SPIRIT V Investigators..

JACC Cardiovasc Interv. 2011 Feb;4(2):168-75. doi: 10.1016/j.jcin.2010.11.006.

16.

Endothelium-dependent and endothelium-independent vasodilator response of left and right internal mammary and internal thoracic arteries used as a composite Y-graft.

Glineur D, Djaoudi S, D'horre W, Gurne O, Delouvroy A, de Kerchove L, El Khoury G, Hanet C.

Eur J Cardiothorac Surg. 2011 Aug;40(2):389-93. doi: 10.1016/j.ejcts.2010.11.055.

PMID:
21277219
17.

Comparison of fractional flow reserve of composite Y-grafts with saphenous vein or right internal thoracic arteries.

Glineur D, Boodhwani M, Poncelet A, De Kerchove L, Etienne PY, Noirhomme P, Deceuninck P, Michel X, El Khoury G, Hanet C.

J Thorac Cardiovasc Surg. 2010 Sep;140(3):639-45. doi: 10.1016/j.jtcvs.2009.11.013.

18.

Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.

Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H, Koolen J, Hauptmann KE, Wijns W, Morice MC, Carrie D, van Es GA, Nagai H, Detiege D, Paunovic D, Serruys PW; NOBORI 1 Clinical Investigators..

Circ Cardiovasc Interv. 2009 Jun;2(3):188-95. doi: 10.1161/CIRCINTERVENTIONS.108.823443.

19.

Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation.

Camenzind E, Wijns W, Mauri L, Boersma E, Parikh K, Kurowski V, Gao R, Bode C, Greenwood JP, Gershlick A, O'Neill W, Serruys PW, Jorissen B, Steg PG; PROTECT Steering Committee and Investigators..

Am Heart J. 2009 Dec;158(6):902-909.e5. doi: 10.1016/j.ahj.2009.10.002.

PMID:
19958855
20.

Comparison of minimally invasive direct coronary artery bypass surgery with implantation of drug-eluting stentsin patients with left anterior descending coronary artery disease.

Etienne PY, Glineur D, Papadatos S, Kalscheuer G, Mairy Y, Boodhwani M, Khoury GE, Noirhomme P, Hanet C.

Innovations (Phila). 2009 Nov;4(6):340-4. doi: 10.1097/IMI.0b013e3181c49e8b.

PMID:
22437232

Supplemental Content

Loading ...
Support Center